Claims for Patent: 9,724,864

Summary for Patent: 9,724,864

Title:	Bioabsorbable polymeric composition and medical device
Abstract:	A method for fabricating an embodiment of a medical device comprising the steps of: preparing a biodegradable polymeric structure; coating the biodegradable polymeric structure with a polymeric coat including a pharmacological or biological agent; cutting the structure into patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.
Inventor(s):	Cottone; Robert J. (Davie, FL), Thatcher; G. Lawrence (Chelmsford, MA)
Assignee:	OrbusNeich Medical, Inc. (Fort Lauderdale, FL)
Application Number:	14/197,357
Patent Claims:	1. A method for making a polymeric scaffold comprising the steps of: blending a polymer composition comprising a crystallizable polymer composition comprising a base polymer of poly L-lactide, and/or poly D-lactide, and/or poly L-lactide-co-PEG, and/or poly D-lactide-co-PEG, linked with modifying copolymers comprising poly L (or D)-lactide-co-.epsilon.-caprolactone in the form of block copolymers or as blocky random copolymers; and molding or extruding the polymer composition to produce a scaffold; wherein the polymer composition is crystallizable when the scaffold is expanded. 2. The method of claim 1, wherein the blending further comprises blending a pharmacological and/or biological agent into the polymer composition. 3. The method of claim 2, wherein the pharmacological agent is selected from the group consisting of: cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprine, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, pimecrolimus, retinoic acid, vitamin E, rosiglitazone, simvastatins, fluvastatin, estrogen, 17.beta.-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet actor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642, deforolimus, and probucol. 4. The method of claim 2, wherein the biological agent is selected from the group consisting of: antibiotics/antimicrobials, antiproliferative agents, antineoplastic agents, antioxidants, endothelial cell growth factors, smooth muscle cell growth and/or migration inhibitors, thrombin inhibitors, immunosuppressive agents, anti-platelet aggregation agents, collagen synthesis inhibitors, therapeutic antibodies, nitric oxide donors, antisense oligonucleotides, would healing agents, therapeutic gene transfer constructs, peptides, proteins, extracellular matrix components, vasodilators, thrombolytics, anti-metabolites, growth factor agonists, antimitotics, steroids, steroidal antiinflammatory agents, chemokines, proliferator-activated receptor-gamma agonists, proliferator-activated receptor-alpha agonists proliferator-activated receptor-beta agonists, proliferator-activated receptor-alpha-beta agonists, proliferator-activated receptor-delta agonists, NF.kappa..beta., proliferator-activated receptor-alpha-gamma agonists, nonsteroidal antiinflammatory agents, angiotensin converting enzyme (ACE) inhibitors, free radical scavengers, inhibitors of the CX3CR1 receptor and anti-cancer chemotherapeutic agents. 5. The method of claim 1, wherein the blending further comprises blending radio-opaque or radio-detectable material into the polymer composition.

Details for Patent 9,724,864

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2026-10-20